<DOC>
	<DOCNO>NCT00002070</DOCNO>
	<brief_summary>To determine whether co-administration sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) improve tolerance ganciclovir patient previously intolerant neutropenia define absolute neutrophil count le 500 cells/mm3 . To assess improved tolerance ganciclovir associate favorable outcome define delayed time progression retinitis ; confirm safety co-administration ganciclovir GM-CSF ; assess change expression HIV p24 antigen serum number T4+ lymphocytes blood patient receive ganciclovir without GM-CSF .</brief_summary>
	<brief_title>Phase III Ganciclovir +/- rGM-CSF AIDS-Related CMV Retinitis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Patient must follow : AIDS define CDC criterion . Retinitis diagnose study ophthalmologist . Performance status 0 , 1 , 2 . Ability give inform consent suitability intravenous access schedule blood test . Patient may Kaposi 's sarcoma basal skin cancer . Exclusion Criteria Coexisting Condition : Patients follow exclude : Active acute infection require treatment . Corneal , lens , vitreal opacification precludes examination fundus , evidence retinopathy . Malignancy Kaposi 's sarcoma ( KS ) basal skin cancer . Patients follow exclude : Active acute infection require treatment . Corneal , lens , vitreal opacification precludes examination fundus , evidence retinopathy . Malignancy Kaposi 's sarcoma ( KS ) basal skin cancer . Prior Medication : Excluded : Granulocyte macrophage colonystimulating factor ( GMCSF ) . Colony stimulate factor . Interleukin 3 . Excluded within 7 day study entry : Zidovudine ( AZT ) . Trimethoprim / sulfamethoxazole ( TMP / SMX ) . Pyrimethamine . Excluded within 30 day study entry : Biologic response modifier . Cytotoxic agent . Investigational agent . Prior Treatment : Excluded : Radiation therapy . Required within 1 week study entry : One dose ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1991</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Neutropenia</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
</DOC>